ERYTECH Provides Business Update and Reports Financial Highlights for Third Quarter 2016 Post author:admERY Post published:November 3, 2016 Post category:Newsroom ERYTECH today provided a business update and reported its financial results for the quarter ended September 30, 2016. You Might Also Like ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S. April 3, 2013 ERYTECH reported full GRASPA® Phase III results in ALL and provided update on AML Phase IIb at ASCO June 1, 2015 ERYTECH announces three data presentations at the 2015 AACR Annual Meeting March 24, 2015
ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S. April 3, 2013
ERYTECH reported full GRASPA® Phase III results in ALL and provided update on AML Phase IIb at ASCO June 1, 2015
